Back to Studies

IMPAACT 2008

Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

Study Status

Closed to Follow Up

Locality

US & Non-US

DAIDS Number

20735

IND Number

133,017

Clinical Trials Link

Summary

IMPAACT 2008 is a Phase I/II, multisite, randomized controlled study of monoclonal antibody VRC01 combined with antiretroviral therapy in infants. The study is designed to assess the safety of VRC01 administered with ART (through Week 14) and the effect of VRC01 on HIV-1 DNA concentrations in peripheral blood (at Week 14) among HIV-1-infected infants.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...